Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition by Cordani, Marco et al.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 9ava i lab le a t www.sc ienced i rec t . com
ScienceDirect
www.elsevier .com/locate/moloncMutant p53 proteins counteract autophagic mechanism
sensitizing cancer cells to mTOR inhibitionMarco Cordania, Elisa Oppicia, Ilaria Dandoa, Elena Butturinia,
Elisa Dalla Pozzaa, Mercedes Nadal-Serranob,c, Jordi Oliverb,c,
Pilar Rocab,c, Sofia Mariottoa, Barbara Cellinia, Giovanni Blandinod,
Marta Palmieria, Silvia Di Agostinod,**, Massimo Donadellia,*
aDepartment of Neuroscience, Biomedicine and Movement, Biochemistry Section, University of Verona, Verona, Italy
bMultidisciplinar Group of Translational Oncology, University Research Institute on Health Sciences (IUNICS),
University of the Balearic Islands, E07122 Palma de Mallorca, Balearic Islands, Spain
cPhysiopathology of Obesity and Nutrition, CIBERobn (CB06/03), Carlos III Health Research Institute, Spain
dTranslational Oncogenomic Unit, Regina Elena National Cancer Institute-IFO, Rome, ItalyA R T I C L E I N F O
Article history:
Received 1 December 2015
Received in revised form
1 March 2016
Accepted 4 April 2016
Available online 12 April 2016
Keywords:
Autophagy
Mutant p53
Gain-of-function
Cancer
mTOR
AMPK* Corresponding author. Department of Neuro
Grazie 8, 37134 Verona, Italy. Tel.: þ39 045 8
** Corresponding author. Oncogenomic and Ep
Italy. Tel.: þ39 06 52662878; fax: þ39 06 5266
E-mail addresses: diagostino@ifo.it (S. Di
http://dx.doi.org/10.1016/j.molonc.2016.04.00
1574-7891/ª 2016 Federation of European BiA B S T R A C T
Mutations in TP53 gene play a pivotal role in tumorigenesis and cancer development. Here,
we report that gain-of-function mutant p53 proteins inhibit the autophagic pathway favor-
ing antiapoptotic effects as well as proliferation of pancreas and breast cancer cells. We
found that mutant p53 significantly counteracts the formation of autophagic vesicles
and their fusion with lysosomes throughout the repression of some key autophagy-
related proteins and enzymes as BECN1 (and P-BECN1), DRAM1, ATG12, SESN1/2 and P-
AMPK with the concomitant stimulation of mTOR signaling. As a paradigm of this mecha-
nism, we show that atg12 gene repression was mediated by the recruitment of the p50 NF-
kB/mutant p53 protein complex onto the atg12 promoter. Either mutant p53 or p50 NF-kB
depletion downregulates atg12 gene expression. We further correlated the low expression
levels of autophagic genes (atg12, becn1, sesn1, and dram1) with a reduced relapse free sur-
vival (RFS) and distant metastasis free survival (DMFS) of breast cancer patients carrying
TP53 gene mutations conferring a prognostic value to this mutant p53-and autophagy-
related signature. Interestingly, the mutant p53-driven mTOR stimulation sensitized can-
cer cells to the treatment with the mTOR inhibitor everolimus. All these results reveal a
novel mechanism through which mutant p53 proteins promote cancer cell proliferation
with the concomitant inhibition of autophagy.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.science, Biomedicine and Movement, Biochemistry Section, University of Verona, Strada Le
027281; fax: þ39 045 8027170.
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MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 9 10091. Introduction In the presentwork, we ascertain that GOFmutant p53 pro-Table 1 e Tissue of origin and p53 status of cancer cell lines.
Cancer cell lines Tissue origin p53 status Mutation
PaCa3 Pancreas Wild-type None
MCF7 Breast Wild-type None
MiaPaca2 Pancreas Mutated R248W
PaCa44 Pancreas Mutated C176S
Panc1 Pancreas Mutated R273H
Suit-2 Pancreas Mutated R273H
MDA-MB-468 Breast Mutated R273H
SkBr3 Breast Mutated R175H
MDA-MB-231 Breast Mutated R280K
AsPC1 Pancreas Null Gene deleted
H1299 Lung Null Gene deletedMutations in the TP53 gene occur in over 50% of human can-
cers, where most of them are missense mutations resulting in
the expression of mutant forms of p53 (Vousden and Lu, 2002;
Waddell et al., 2015). In addition, p53 mutated proteins acquire
new biological properties referred to as gain-of-function (GOF)
that contribute to the induction and maintenance of cancer
(Santoro et al., 2014). In many human tumors, p53 mutations
are associated with high genomic instability, poor prognosis,
poor response to chemotherapy and accelerated tumor recur-
rence (Ganci et al., 2013; Liu et al., 2012; Walerych et al., 2012).
Different models have been proposed to explain the GOF activ-
ities of mutant p53, including binding and inactivation of the
p53 family members p63 and p73, modulation of the activity
of the transcription factors NF-Y, E2F1, E2F4, p65 NF-kB, and
vitamin D receptor (VDR), or the inactivation of the DNA dam-
age sensor ataxia telangiectasia mutated (ATM) (Di Agostino
et al., 2006; Stambolsky et al., 2010; Strano et al., 2007; Valenti
et al., 2015; Weisz et al., 2007). Recently, we have documented
that DNA damage with gemcitabine stabilizedmutant p53 pro-
tein in cell nuclei triggering chemoresistance and inducing the
expression of cell cycle-related genes, as Cdk1 and CCNB1
increased cell growth (Fiorini et al., 2015b). Autophagy is a
self-eating process by which eukaryotic cells degrade proteins
and cytoplasmic organelles through lysosomal hydrolases,
thus controlling quality of the cytoplasm and recycling macro-
molecules to extract energy and to overcome nutritional or
microenvironmental stressful situations (Viry et al., 2014).
Several studies indicate thatwild type p53 triggers the autopha-
gicmachinery in human cancer cells involvingmany pathways
as the stimulation of the nutrient energy sensor AMP-activated
protein kinase (AMPK), the inhibition of the mammalian target
of rapamycin (mTOR) by up-regulation of PTEN and TSC1, and
the induction of the autophagy-related gene DRAM1 (Comel
et al., 2014; Crighton et al., 2007; Drakos et al., 2009; Gomes
et al., 2015). Interestingly, autophagy regulation is strictly inter-
connected with the aberrant setting of cancer cell metabolism
as revealed by the fact that mTOR and AMPK pathways
are both the master regulators of autophagy and the most
important sensors of the cellular energy status (Dodson et al.,
2013). In particular, mTOR complex stimulates anabolic biosyn-
thesis for cancer cell growth and inhibits autophagy, while
AMPK signaling triggers degradation of macromolecules,
including lysosomal autophagic catabolism (DeBerardinis and
Thompson, 2012). Recently, Zhou et al. have shown that GOF
mutant p53 inhibited AMPK signaling in head and neck cancer
cells directly binding to the AMPKa subunit thus stimulating
anabolic growth and gaining its oncogenic function (Zhou
et al., 2014). Other studies demonstrated the involvement of
mutant p53 in the regulation of cancermetabolism, throughout
the transcriptionalmodulation of SREBP1, a downstream target
of AMPK (Freed-Pastor et al., 2012). However, despite a study
describing a correlation between the subcellular localization
of overexpressed p53 mutant proteins and the regulation of
autophagy (Morselli et al., 2008), the functional involvement
of endogenous mutant p53 in the regulation of autophagy in
cancer cells and the identification of the associated molecular
mechanisms remain largely unknown.teins are able to orchestrate a plethora of events addressed to
counteract autophagy in the various phases of the process,
thus contributing to inhibit apoptosis and to sustain onco-
genic activity. Notably, we document that mutant p53 inter-
acts with the p50 NF-kB subunit onto the atg12 promoter
inhibiting its expression and resulting in the repression of
the autophagic machinery. Furthermore, we point out that
cancer cells bearing endogenous mutant p53 are more sensi-
tive to mTOR inhibition than cancer cells expressing wild
type p53 protein, providing a conceivable personalized ther-
apy for cancer patients carrying GOF mutations of TP53 gene.2. Material and methods
2.1. Chemicals
Chloroquine diphosphate (CQ), 3-methyladenine (3MA), and
everolimus (EVE; RAD-001) were obtained from Sigma (Milan,
Italy). Compound C (CC) solution was obtained from Calbio-
chem (Merck; Darmstadt, Germany).
2.2. Cell culture
PaCa3 (WTp53), Panc1 (mutant p53-R273H), PaCa44 (mutant
p53-C176S), MiaPaCa2 (mutant p53-R248W), Suit-2 (mutant
p53-R273H) and AsPC1 (p53-null) human pancreatic adenocar-
cinoma cell lines were grown in RPMI medium (Life Technolo-
gies, Milan, Italy), while lung cancer H1299 (p53-null), breast
cancer MCF7 (WTp53), SKBr3 (mutant p53-R175H), MDA-MB-
468 (mutant p53-R273H) and MDA-MB-231 (mutant p53-
R280K) cell lines were cultured in DMEM medium (Life Tech-
nologies, Milan, Italy). Both culturemedia were supplemented
with 10% FBS, and 50 mg/ml gentamicin sulfate (BioWhittaker,
Lonza, Bergamo, Italy). Cell lines were incubated at 37 C with
5% CO2. The list of the cell lines used in this study and their
p53 status are summarized in Table 1.
2.3. Cell proliferation assay
Cells were seeded in 96-well plates (5  103 cells/well) and
the day after were incubated with various compounds at
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constructs (see figure legends). At the end of the treatments,
cell growth was measured by Crystal Violet assay (Sigma,
Milan, Italy) according to the manufacturer’s protocol, and
absorbance was measured by spectrophotometric analysis
(A595nm).
2.4. Transient transfection assays
Exponentially growing cells were seeded at 5  103 cells/well
in 96-well plates or at 2.5  105 cells in 60 mm cell culture
plates. The ectopic expression of mutant p53 in p53-null can-
cer cells was carried out transfecting pcDNA3-mutp53R273H
or pcDNA3-mutp53R175H expression vectors, or their relative
negative control (pcDNA3). The ectopic expression of wild
type or dominant negative (DN)-AMPK subunit g2 was ob-
tained by transfection of the pcDNA5/FRT expression vector
containing the human wild type AMPK g2 subunit or the
mutated R531G protein which were kindly provided by Dr.
Hawley (University of Dundee, Scotland, UK). Wild-type and
mutant p53 protein expression was transiently knocked-
down by transfection with pRSUPER-p53 or pLVTHM-p53 vec-
tors or their negative controls (pRSUPER or pLVTHM), kindly
provided by Dr. Agami (The Netherlands Cancer Institute,
Amsterdam) (Brummelkamp et al., 2002) and by Dr. Sergio
Ruiz (CNIO, Madrid, Spain), respectively. Commercial siRNA
smart pool of three oligonucleotides (si-p53) transiently tar-
geting p53 (Santa Cruz Biotech. sc-29435) was used in the ex-
periments of RT-qPCR to exclude back-side effects and to
confirm the robustness of the data. A si-GFP as non-
silencing control 50-GGCTACGTCCAGGAGCGCACC-30 was
used as a negative control. The silencing transfections were
carried out for 48 h using Lipofectamine 2000 (Life Technolo-
gies), according to the manufacturer’s instructions. Knock-
down of Atg5 expression was performed by shRNA-Atg5
cloned in pMSCV-Puro-miR30 vector (or its negative empty
vector) kindly provided by Dr. Hans-Uwe Simon (University
of Bern, Switzerland) (Maskey et al., 2013). Knock-down of
Beclin1 expression was obtained by transfecting cells with
specific Beclin1 small interfering (si) RNA having the following
sequences: 50-ACAGUGAAUUUAAACGACAGCAGCU-30 and 50-
AGCUGCUGUCGUUUAAAUUCACUGU-30 and with a siRNA-
CTRL (negative control): 50-CAGUCGCGUUUGCGACUGG-30
purchased from Life Technologies. Knock-down of p50 NF-kB
subunit expression was obtained by transfecting cells with a
specific 21-nt-long interfering RNA duplex with two 3’-end
overhang dT nucleotides. The sequence of the antisense
strand of the anti-p50 siRNA was 50-AGUCCAG-
GAUUAUAGCCCCdTdT-3’ (MWG Biotec, Ebersberg, Germany;
or Dharmacon, Lafayette, CO) as reported (Laderach et al.,
2003). Cells were transfected by siRNAs at a final concentra-
tion of 50 nMusing Lipofectamine 2000 (Life Technologies), ac-
cording to the manufacturer’s instructions.
2.5. RNA isolation and quantitative real-time PCR
analysis
Total RNAwas extracted from cells using TRIZOL Reagent (Life
Technologies) in accordance with the manufacturer’s instruc-
tions. Five micrograms of total RNA were reverse-transcribedat 37 C for 60 min in the presence of random hexamers and
Moloney murine leukemia virus reverse transcriptase (Life
Technologies). Transcripts were measured by real-time PCR
using the SYBR Green assay (Applied Biosystems, Carlsbad,
CA, USA) with a StepOne instrument (Applied Biosystems).
PCR analysis was carried out using specific oligonucleotides
for the genes listed in Supplementary Table 1. The primers
were designed with Primer3 version 0.4.0 (http://frodo.wi.mi-
t.edu/primer3/). All primer sets worked under identical quan-
titative PCR cycling conditions with similar efficiencies to
obtain simultaneous amplification in the same run. The
2DDCT method for relative quantification of gene expression
was used to determine mRNA expression levels. GAPDH
gene expression was used as endogenous control to stan-
dardize mRNA expression. All reactions were performed in
duplicate from three independent experiments.
2.6. ChIP experiments
1% formaldehyde cross-linking and chromatin immunopre-
cipitations were performed as described in (Di Agostino
et al., 2006; Valenti et al., 2011). The chromatin solution was
immunoprecipitated with sheep anti-p53 Ab7 (Millipore, Bill-
erica, MA, USA), rabbit anti-p50 (Santa Cruz Biotech. SC-
7178), rabbit anti-p65 (Santa Cruz Biotech. SC-372), or no anti-
body as negative control. The immunoprecipitations were
performed using Pierce ChIP-grade Protein A/G magnetic
beads (Thermo Fisher Scientific, Rockford, IL, USA). Primers
used for the amplification of the different regulatory regions
are listed in Supplementary Table 2. NF-kB p50 Region 2
consensus sequence on ATG12 promoter was selected from
the literature andNF-kB p50 Region 1, the consensus sequence
was identified byMatInspector software (www.genomatix.de).
The promoter occupancy was analyzed by RT-qPCR using the
Fast SYBR Green assay (Applied Biosystems, Carlsbad, CA,
USA) and the StepOne Real-Time PCR System (Applied Bio-
systems). Normalization was performed to the amount of
input chromatin. The ChIP results were further normalized
on the qPCR of a H1H2B2, the genic region resulted negative
for the recruitment of mutant p53 (Supplementary Figure 1)
(Biagioni et al., 2012).
2.7. Immunoblot analysis
Cells were harvested, washed in PBS, and re-suspended in
lysis buffer in the presence of phosphatase and protease in-
hibitors (50 mM TriseHCl pH 8, 150 mM NaCl, 1% Igepal CA-
630, 0.5% Na-Doc, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF,
2.5 mM EDTA, 1mM PMSF, and 1 protease inhibitor cocktail).
After incubation on ice for 30 min, the lysates were centri-
fuged at 14,000 g for 10min at 4 C and the supernatant frac-
tions were used for Western blot analysis. Protein
concentration was measured by Bradford reagent (Pierce,
Milan, Italy) using bovine serum albumin as a standard. Pro-
tein extracts (50 mg/lane) were resolved on a 12% SDS-
polyacrylamide gel and electro-blotted onto PVDFmembranes
(Millipore, Milan, Italy). Membranes were blocked in 5% low-
fat milk in TBST (50 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween
20) for 1 h at room temperature and probed overnight at 4 C
with a mouse polyclonal anti-p53 (1:500) (Santa Cruz, #sc-
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#2775), rabbit polyclonal anti-phospho(Ser15)Beclin1 (1:1000)
(Cell Signaling #13825) rabbit polyclonal anti-Beclin1 (1:1000)
(GeneTex, #GTX113039), rabbit monoclonal glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (1:1000) (Cell Signaling,
#5174S), rabbit monoclonal anti-phospho (Thr172)AMPK
(1:1000) (Cell Signaling #2535), rabbit monoclonal anti-AMPK
(1:1000) (Cell Signaling #2603), mouse monoclonal anti-
phospho (Thr389)p70S6K (1:1000) (Cell Signaling #9206), rabbit
monoclonal anti-p70S6K (1:1000) (Cell Signaling #2708), rabbit
polyclonal anti-SESN1 (1:1000) (GeneTex #GTX116926), rabbit
polyclonal anti-SESN2 (1:1000) (GeneTex #118141), rabbit poly-
clonal anti-NF-kB p50 (1:1000) (Santa Cruz #sc-7178), rabbit
polyclonal anti-NF-kB p65 (1:1000) (Santa Cruz #sc-372), mouse
monoclonal anti-alpha-tubulin (1:2500) (Oncogene #CP06), or
rabbit monoclonal anti-phospho (Tyr705)STAT3 (1:1000) (Cell
Signaling #9131) antibodies.
Horseradish peroxidase conjugated anti-mouse or anti-
rabbit IgGs (1:8000 in blocking solution) (Upstate Biotech-
nology, Milan, Italy) were used as secondary antibodies.
Immunodetection was carried out using chemiluminescent
substrates (Amersham Pharmacia Biotech, Milan, Italy) and
recorded using a HyperfilmECL (Amersham Pharmacia
Biotech). ECL results were scanned and the amount of each
protein band quantified using NIH Image J software (http://
rsb.info.nih.gov/nih-image/).
2.8. Immunoprecipitation assay
Cell extracts were solubilized in lysis buffer with 150 mM
Hepes pH 7.5, 300 mM NaCl, 1% Triton-X100, phosphatase
and protease inhibitors. Cells were harvested and lysed by
sonication in lysis buffer and cleared by centrifugation. Pro-
tein concentrations were determined by colorimetric assay
(Bio-Rad, Hercules, CA, USA). For each immunoprecipitation,
1 mg of antibody and 1 mg of rabbit or sheep IgG (Santa Cruz
Biotech) were used as controls. To immunoprecipitate, we
used rabbit polyclonal anti-p50 (sc-7178) from Santa Cruz
Biotech and sheep polyclonal anti-p53 Ab7 (PC35-1EA) from
Millipore. 1 mg of pre-cleared extracts were diluted in lysis
buffer containing 0.05% BSA and incubated with protein A/
G-Agarose beads (Thermo Fisher Scientific, Rockford, IL,
USA) and antibodies, under constant shaking at 4 C for
3 h. Bead-bound immunocomplexes were rinsed with lysis
buffer and eluted in 50 ml of SDS sample buffer for Western
blotting. Western blotting was performed using the following
primary antibodies: mouse monoclonal p53 (DO1), GAPDH
(Santa Cruz Biotech), rabbit polyclonal anti-NF-kB p65
(1:1000) (Santa Cruz #sc-372), rabbit polyclonal anti-p50 (sc-
7178) and actin (Sigma) antibodies. Western blot analysis
was performed with the aid of the enhanced chemilumines-
cence system (Thermo Fisher Scientific, Rockford, IL, USA)
and the acquisition of the images by Uvitec technology
(Eppendorf).
2.9. Apoptosis assay
Cells were seeded in 96-well plates (5 103 cells/well).
Twenty-four hours later, cells were treated as indicated in
the figure legends. At the end of the treatment, cells werefixed with 2% paraformaldehyde in PBS for 30 min at room
temperature, washed twice with PBS and stained with
annexinV/FITC (Bender MedSystem, Milan, Italy) in binding
buffer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, and
2.5 mM CaCl2) for 10 min at room temperature in the dark.
Cells were then washed with binding buffer and fluores-
cence was measured using a multimode plate reader
(Ex485nm and Em535nm) (GENios Pro, Tecan, Milan, Italy).
The values were normalized on cell proliferation by Crystal
Violet assay.
2.10. Monodansylcadaverine staining and
autophagosome formation assay
To quantify the induction of autophagy, cells were incubated
with the fluorescent probe monodansylcadaverine (MDC;
Sigma, Milan, Italy), accordingly with the guidelines for study-
ing autophagy (Klionsky et al., 2016). MDC is a selectivemarker
for acidic vesicular organelles, such as autophagic vacuoles.
Briefly, cells were seeded in 96-well plates (5  103 cells/well)
and treated with various compounds as indicated in the figure
legends. At the end of the treatments, cells were incubated in
culture medium containing 50 mM MDC at 37 C for 15 min.
Cells were then washed with Hanks buffer (20 mM Hepes pH
7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM KCl, and 1 mM
CaCl2) and fluorescence was measured using a multimode
plate reader (Ex340nm and Em535nm) (GENios Pro, Tecan, Milan,
Italy). The values were normalized for cell proliferation by
Crystal Violet assay.
2.11. Acridine orange staining and autolysosome
detection
Cells were seeded in a 24-well plate on glass cover-slips at a
density of 6  104/well. After 24 h, cells were transfected
with pRSUPER-p53 or with the empty pRSUPER vector by using
Lipofectamine 2000 according to the manufacturer’s instruc-
tions. 48 h after transfection cells were rinsed in phosphate
buffer saline (PBS) and stained with 6 mg/ml acridine orange
(AO). Cell images were captured using a fluorescence micro-
scope Leica DM6000 (Leica Microsystem, Manheim, Germany)
at 40 magnification and processed using Adobe Photoshop
and NIH Image J software.
To quantify autolysosome formation, cells transfected
with pRSUPER-p53 vector or its negative control (pRSUPER)
were stained with AO following the manufacturer’s in-
structions. Quantification of autolysosomes was per-
formed measuring the red/green fluorescence intensity
ratio of AO staining (AO green fluorescence Ex485nm and
Em535nm; AO red fluorescence Ex430nm and Em590nm) with
a multimode plate reader (GENios Pro, Tecan, Milan, Italy).
Values were normalized on cell proliferation by crystal vi-
olet assay.
2.12. LC3-GFP and lysosome co-localization analysis
Cells were seeded in a 24-well plate on glass cover-slips at
a density of 6  104/well. After 24 h, cells were co-
transfected with pEGFP-LC3B and pRSUPER-p53 vector or
with pEGFP-LC3B and the pRSUPER empty vector by using
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structions. 48 h after transfection, lysosomes were stained
with 50 nM Lysotracker-RED-DN99 (Life Technologies) and
nuclei were stained with 0.1 mg/ml Hoechst (Life Technolo-
gies). Cells were than rinsed in PBS and fixed in 4% (w/v)
paraformaldehyde. Cover-slips were mounted over slides
in AF1 medium (Dako). Cell images were captured using a
confocal laser-scanning fluorescence microscope Leica
SP5 (Leica Microsystem, Manheim, Germany) at 63 magni-
fication and processed using Adobe Photoshop and NIH Im-
age J software.
2.13. mRNA expression data
We used the publicly available data sets: GSE22358 (Gluck
et al., 2012) and GSE31812 (Freed-Pastor et al., 2012). The
data sets were analyzed by the Oncomine platform www.on-
comine.org (Rhodes et al., 2004). The mRNA expression data
were measured using Agilent UNC Perou Lab Homo sapiens
1  44K Custom Array and Human Gene 1.0 ST arrays,
respectively.
2.14. Kaplan-Meier analysis
Gene expression dataset raw data and survival information
of 108 BCL patients with TP53 mutated were downloaded
from GEO (http://www.ncbi.nlm.nih.gov/geo/) and the
Kaplan-Meier analysis was performed by using the on-line
tool www.kmplot.com (Gyorffy et al., 2010) where eight pub-
lic datasets were considered. Gene expression profiles were
performed by using Affymetrix HG-U133A (GPL96) and HG-
U133 Plus 2.0 (GPL570) microarrays were only considered.
The latter are the most frequently used and have 22,277
probe sets in common. To analyze the prognostic value of
genes, the cohorts were divided into two groups according
to the median (or upper/lower quartile) expression of gene
signature considered. The two groups were compared in
terms of relapse free survival (RFS) and distant metastasis
free survival (DMFS). A survival curve was displayed, and
the hazard ratio with 95% confidence intervals and logrank
P value are calculated. P values < 0.05 were considered sta-
tistically significant.
2.15. Statistical analysis
ANOVA (post hoc Bonferroni) analysis was performed by
GraphPad Prism 5 software. Student’s t-test (two-tailed) was
also conducted. P value < 0.05 was indicated as statistically
significant. Values are the means of three independent exper-
iments (SD).3. Results
3.1. Gain of function p53 mutant proteins inhibit the
autophagic vesicles formation in cancer cells
To study the functional role of GOFmutant p53 proteins in the
autophagic mechanism, we first analyzed the endogenous
level of autophagosome vesicle formation by staining diversecancer cell lines with the fluorescent probe MDC. Cancer cells
with different missense mutations of TP53 gene had the
endogenous level of autophagosome vesicles about 5e6 folds
lower than cells with wild type TP53 alleles (Figure 1A).
When PaCa3 and MCF7 cell lines (expressing a wild type p53
protein) were knocked down for p53 expression, the autopha-
gosome formation was inhibited, accordingly with the litera-
ture (Figure 1B and C) (Crighton et al., 2007). Conversely, the
autophagosome formation was significantly increased after
knock-down of GOF mutant p53 in six cancer cell lines
(Figure 1B and C). Consistent with this, overexpression of
mutant p53 R175H or R273H proteins in AsPC1 cells (null for
p53 expression) produced a drastic reduction of MDC probe
incorporation revealing an inhibitory role of mutant p53 of
the autophagic process (Figure 1B and C). To further support
the idea that mutant p53 may have a role in the inhibition of
the autophagic event, we analyzed the expression of the auto-
phagic receptor/adaptor SQSTM1/p62 (sequestosome 1),
whose massive accumulation is usually a consequence of
autophagy impairment and accumulation of aggregated struc-
tures positive for ubiquitin (Katsuragi et al., 2015). Accord-
ingly, we observed that mutant p53 knockdown triggered
p62 expression decrease (Figure 1D). Furthermore, we evalu-
ated the expression levels of the lipidated and truncated iso-
form II of light chain 3 protein (LC3-II), which is functionally
involved in the formation and maturation of autophagic vesi-
cles. Our findings showed that LC3-II protein expression levels
considerably decreased in AsPC1 cells after ectopic expression
of mutant R175H or R273H p53 proteins while increased in
mutant p53-knocked down cells (Figure 1D). We also observed
that chloroquine (CQ) further increased the amount of LC-II in
silencing mutant p53 conditions (Figure 1D), accordingly with
the hypothesis of the autophagic inhibitory flux inside the
blockage of the lysosomal degradation. According to this,
confocal microscopy analysis revealed that mutant p53 coun-
teracts the fusion between autophagic vesicles (identified by
LC3-GFP overexpression) and lysosomes (identified by lyso-
tracker red probe) since the merged image of Panc1-
shp53 cells showed a significant co-localization of LC3-II
with lysosomes represented by yellow puncta and confirmed
by the RGB profile (Figure 1E). In Supplementary Figure 2, we
included a negative control about formation of autophagic
vesicles after knock-down of mutant p53 in the absence or
presence of the autophagy inhibitor 3-methyladenine.
Furthermore, we have examined the formation of autolyso-
somes (autophagic vesicles joined with lysosomes) using the
fluorescent probe acridine orange (AO), which changes its
fluorescence emission from green to red upon accumulation
into lysosomal acidic compartments. The typical pH acidifica-
tion of lysosomes during autophagic stimulation has been
examined by AO probe staining in knocked down mutant
p53 conditions (Figure 1F and G). Figure 1F showed that
mutant p53 cell lines (Panc1 and SKBr3) had a high red/green
fluorescence ratio in the sh-p53 condition, conversely wild
type p53 cells (MCF7) showed a decrease of the autolysosome
formation (Figure 1F). Themicroscopy experiments confirmed
these results revealing the presence of red areas (acidic lyso-
somes containing accumulation of AO probe) into the cyto-
plasm of the cells interfered for mutant p53 expression
(Figure 1G). Overall these data strongly support the hypothesis
Figure 1 eMutant p53 counteracts autophagy. (A) The endogenous basal level of autophagosomes in cancer cells carrying WT or mutant p53 was
analyzed using the incorporation of the fluorescent probe monodansylcadaverine (MDC). Cells were seeded in 96-well plates, incubated overnight,
and stained with MDC as described in Material and Methods. (B) Cells were transfected with the pRSuper-p53 vector (shp53) to knockdown p53
expression (see Material and Methods) or with plasmids coding mutp53R175H, mutp53R273H proteins, or their relative negative controls
(shCTRL or mock, respectively). Autophagosome formation assay was performed using the incorporation of MDC probe. (C) Western blot of p53
using the protein extract of the samples used for (B) to test the effective knock down of WT or mutant p53 and the overexpression of mutant p53 in
the various cell lines indicated. (D) Panc1 cells were transfected with pRSuper-p53 vector (shp53) or its negative control (shCTRL) and AsPC-
1 cells with plasmids for mutant p53 overexpression or its mock vector. Panc1 cells were pre-treated with 5 mM chloroquine (CQ) for 1 h before cell
transfection. Whole-cell extracts were used for Western blot analysis of the autophagic proteins p62/SQSTM1 and LC3 (isoforms I and II), p53
and GAPDH (as control loading). (E) 48 h after co-transfection with plasmids coding for LC3-GFP and pRSuper-p53 vector (shp53) or LC3-GFP
and the empty vector (negative control; CTRL), Panc1 cells were fixed. Lysosomes and nuclei were stained with Lysotracker (red) and Hoescht
(blue), respectively. The RGB profile plotted along the dashed line drawn in the merge image is also shown. Merge and single channel images
come from a single z-plane. Scale bar 10 mm. (F) Autolysosome formation analyzed by red/green fluorescence intensity ratio quantification of
acridine orange (AO) staining in the indicated cells transfected with pRSuper-p53 vector (shp53) or with its negative control (shCTRL). (G) 48 h
after the p53 depletion Panc1 cells were stained with an AO solution (1:1500 in PBS) and observed at 403 magnification. Scale bar 40 mm. All the
experiments presented in this figure are representative of three biological replicates. P-values were calculated with two-tailed t-test. Statistical
analysis: *p< 0.05 shp53 vs shCTRL; xp< 0.05 R175H or R273H vs mock.
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the formation of the autophagic vesicles and their fusion with
lysosomes in cancer cells.
3.2. Autophagy inhibition by mutant p53 increases the
proliferation of cancer cells
Mutant p53 proteins have been implicated in the induction of
cell proliferation, chemoresistance, disruption of tissue archi-
tecture, promotion ofmigration, invasion andmetastasis, and
several other pro-oncogenic properties (Adorno et al., 2009; Di
Agostino et al., 2006; Freed-Pastor and Prives, 2012; Girardini
et al., 2011; Walerych et al., 2012). In this study, we considered
cancer cell lines where the role of tumor suppressor wild type
p53 and oncogenic mutant p53 in the regulation of cell prolif-
eration was well assessed (Supplementary Figure 3) (Cadwell
and Zambetti, 2001; Levine, 1997; Muller and Vousden, 2013).
To unravel the possible biological role of autophagy inhibition
in the aberrant proliferation induced by mutant p53, we
knocked-down the essential autophagic protein Atg5 in
Panc1, MiaPaCa2, and MDA-MB-468 cells (Mizushima et al.,
1998). The MDC assay established that Atg5 knockdown effec-
tively repressed the autophagosome formation triggered by
mutant p53 downregulation (Figure 2A; Supplementary
Figure 4). Importantly, the depletion of Atg5 caused a rever-
sion of cell growth inhibition (Figure 2B) and a decrease of
the apoptosis (Figure 2C) stimulated by mutant p53 knock-
down. These findings indicated that autophagy inhibition
strongly contributed to the increased proliferation and to the
concomitant down-regulation of the apoptotic stimuli driven
by mutant p53. Similar results are also observed using 3-
methyladenine (3MA) as autophagy inhibitor at non-toxic
concentrations (Supplementary Figure 2).
3.3. Mutant p53 protein inhibits the expression of
autophagic genes in tumoral cell lines and cancer patients
Autophagic pathway is a complex sequence of biological
events leading to formation, maturation and fusion of auto-
phagosomes with lysosomes to allow the degradation and
recycling of cellular components (Viry et al., 2014). These
events are driven by a number of autophagy-related genes
(ATGs), which are mostly transcriptionally induced by auto-
phagic stimuli such as nutritional deprivation, infections or
metabolic and oncogenic stress (Galluzzi et al., 2015). In the
present study, we have shown that tumor cells carrying
mutant p53 proteins escaped autophagic activity (Figures 1
and 2). In order to investigate the role of mutant p53 in auto-
phagy inhibition, we studied whether mutant p53 proteins
could control the expression of some crucial ATGs, as atg12,
becn1, sesn1, sesn2 and dram1 genes. The depletion of mutant
p53 by p53 siRNA smart pool oligos transfection (sip53), deter-
mined an increase of the mRNA expression in most of these
ATGs in Panc1, MDA-MB-468 and SKBr3 cell lines (Figure 3A,
Supplementary Figure 5). In these cell lines, we have checked
the CCNB1 mRNA expression as a control of our cellular sys-
tems (Supplementary Figure 6). Cyclin B protein is related to
the cell cycle proteins, important for the control of the cell cy-
cle progression, and is a well-established mutant p53 target
gene (Di Agostino et al., 2015; Di Agostino et al., 2006).Conversely, the depletion ofWTp53 expression inMCF7 breast
cancer cell line led to a general decrease of the expression of
ATGs (Figure 3A, Supplementary Figure 5). Accordingly,
ectopic expression of mutp53R175H or mutp53R273H in p53-
null H1299 cells led to a significant reduction of ATGs tran-
scripts (Figure 3A, Supplementary Figure 5, Supplementary
Figure 6). To further investigate the inverse relationship be-
tween the expression of mutant p53 and two representative
ATGs (atg12 and becn1 transcripts), we queried public gene
expression data repositories (http://www.oncomine.org/)
(Rhodes et al., 2004). In Figure 3B, we reported that atg12 and
becn1 transcripts increased substantially in three separate bio-
logical clones of MDA-MB-468 breast cancer cells (carrying
mutp53R273H) where the mutant p53 knock-down was
induced by doxycycline (DOX) [our elaboration of the data
set from Freed-Pastor and colleagues published in (Freed-
Pastor et al., 2012)]. This result was further corroborated by
our additional analysis of the data set from Gluck et al.
(Gluck et al., 2012). where atg12 and becn1 transcripts were
significantly down-regulated in breast cancer patients car-
rying mutant p53, compared to those with WTp53
(Figure 3C). Altogether these data strongly confirm the inhibi-
tory role of mutant p53 in vitro and in vivo on the expression
level of ATGs. Moreover, to test the hypothetical prognostic
value of ATGs in cancer patients, we considered a gene
expression signature (atg12, becn1, sesn1, and dram1) by select-
ing autophagy-related genes that were up-regulated by
mutant p53 depletion in Figure 3A. About 70% of the breast
cancer alterations in TP53 are missense mutations (TCGA)
and where only missense mutations compared to the frame-
shift and non-sense mutations have been demonstrated to
have Gain-Of-Function activities (Bertheau et al., 2013). It is
for this reason why we focused our attention only on a sub-
group of breast cancer patients expressing mutant p53 pro-
teins independent by intrinsic subtype (luminal, basal-like,
Herþ) to assess the potential correlation between the experi-
mental autophagic gene signature and the patient’s clinical
outcome (Figure 3D). We analyzed gene expression datasets
and survival information downloaded from GEO and sorted
for the presence of TP53 gene mutations (www.ncbi.nlm.nih.-
gov/geo/) (www.kmplot.com) (Gyorffy et al., 2010). To analyze
the prognostic value of the signature, we split patients into
two groups (high and low expression levels of autophagic
gene signature) by the median of the expression values. The
two groups were then compared in terms of relapse free sur-
vival (RFS) and distant metastasis free survival (DMFS). KM
analysis in the Figure 3D showed that low atg12, dram1,
sesn1 and becn1 signature expression was significantly associ-
ated with a poor prognosis in the mutant p53 breast cancer
subgroup (RFS Statistically significant results with p-
value ¼ 0.02, N ¼ 188; DMFS Statistically significant results
with p-value ¼ 0.0028, N ¼ 83).
3.4. Mutant p53 inhibits atg12 expression by interaction
with NF-kB p50 subunit
We and others have shown that mutant p53 binds to the pro-
moters of its target genes through cooperatingwith other tran-
scription factors, such as E2F1, NF-Y, Sp1 and others (Di
Agostino et al., 2006; Stambolsky et al., 2010; Strano et al.,
Figure 2 e Impact of autophagy inhibition by mutant p53 on cell
growth and apoptosis. Panc1, MiaPaCa2 and MDA-MB-468 cell
lines were seeded in 96-well plates and transfected with pRSuper-p53
vector (shp53) and/or pMSCV-Puro-miR30-Atg5 (shAtg5), or their
relative negative controls (shCTRL) for 48 h. Autophagosome
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 9 10152007; Valenti et al., 2015; Weisz et al., 2007). Recently, we have
also shown thatmutant p53was able to repress theDNA repair
gene expression by the association with the transcriptional
repressor E2F4 (Valenti et al., 2015). Since ATG12 is an essential
mediator of the initial phases of autophagosome vesicle
formation, we studied this gene looking for promotorial
consensus regions binding transcriptional repressors. Our in
silico analysis by using MatInspector software (www.genoma-
tix.de) revealed the presence of two NF-kB p50 specific
consensus sequences in the atg12 promoter: atg12 promoter
Region 1 (1055 bp) and atg12 promoter Region 2 (513 bp)
(Figure 4A). MatInspector software uses TRANSFAC matrix
thatwasable todiscriminate between the specificity of binding
between NF-kB p50 and NF-kB p65 factors conferring different
and specific position frequency to the nucleotides belonging to
the promotorial consensus sequence (Supplementary
Figure 7). As NF-kB p50 usually acts as a transcriptional
repressor (Elsharkawy et al., 2010; Tong et al., 2004), we studied
its recruitment onto the atg12 promoter. Chromatin immuno-
precipitation experiments (ChIP) in SKBr3 cells revealed that
p50 was actually bound to both two binding regions of atg12
promoter and that this protein-DNA interaction was removed
by transfection of siRNAp50 oligos (Figure 4B; Supplementary
Figure 1A). Notably, ChIP assay showed that also mutant p53
proteinwas recruited onto p50 consensus sites and its binding
decreased after p50 depletion (Figure 4B). As expected by the in
silico analysis, NF-kB p65 did not bind the two atg12 promoter
regions instead recruited NF-kB p50 (Figure 4B). The same re-
sults were observed in the ChIP experiment in Panc1 cells
(Supplementary Figure 1B). In order to support new evidence
that mutant p53 and p50 bind onto the atg12 gene promoter,
we aimed to investigate the existence of a novel floating
mutp53/p50 protein complex. Coimmunoprecipitation experi-
ments fromwhole protein extracts of Panc1 and SKBr3 cancer
cell lines endogenously expressing p53 mutant proteins
revealed the formation of a mutp53/p50 protein complex
(Figure 4C). NF-kBp65wasnot detected in this protein complex
in any coimmunoprecipitation conditions, confirming its
absence on the atg12 promoter previously discussed
(Figure 4C). The formation of endogenousmutant p53/p50 pro-
tein complex was further observed also in MDA-MB-468 and
MDA-MB-231 cancer cells (Supplementary Figure 8). We sup-
ported this result by also showing the formation of the com-
plex between the overexpressed mutp53R175H and
endogenous p50 proteins in H1299 cells (Figure 4C). Strik-
ingly, the depletion of p50 led to the resumption of atg12
mRNA transcription in mutant p53 Panc1 and MDA-MB-
468 cells (Figure 4D). According to the above results, the p50
knock down had a functional effect on the increase of auto-
phagosome formation only in SKBr3 and Panc1 cells (bearing
mutant p53), thus supporting the inhibitory role of mutant
p53/p50 complex in the autophagic process (Figure 4E).formation (A), cell growth (B), and apoptosis (C) were determined
using MDC assay, crystal violet colorimetric assay and annexinV/
FITC binding assay, respectively. All the experiments presented in
this Figure are representative of three biological replicates. P-values
were calculated with two-tailed t-test. Statistical analysis: *p< 0.05
shp53 vs shCTRL; xp< 0.05 shp53DshATG5 vs shp53.
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mTOR signaling
In order to examine whether mutant p53 impinged in the
crucial regulatory kinase complexes of the autophagic process
we analyzed the protein expression and the phosphorylation
state in different cancer cell lines expressing wild type or p53
mutant proteins. We found that the knock down of mutant
p53 ineitherPanc1andSKBr3cell lines led toan increaseofSes-
trin1 and Sestrin2 protein levels, while silencing of wild type
p53 in PaCa3 and MCF7 cancer cells resulted in a general
down-regulation of Sestrin protein levels (Figure 5A). Sestrins
are a classof proteins that candirectly interactwithAMPKsub-
units favoring their phosphorylation by upstream kinases and
thereby resulting in AMPK signaling stimulation (Budanov and
Karin, 2008; Morrison et al., 2015; Sanli et al., 2012). To deter-
mine whether mutant p53 could affect the phosphorylation
ofAMPK,we analyzed the level of phospho-AMPKa (Thr172) af-
ter modulation of mutant or wild type p53 expression. We
observed that depletion of mutant p53 was able to increase
the phosphorylation level of AMPK [P(Thr172)-AMPK/AMPK]
and to decrease that of p70S6K [P(Thr)389-p70S6K/p70S6K], a
direct target of mTOR signaling (Figure 5A). Similar results
were obtained with pLVTHM-p53 vector confirming data
observed with pRSUPER-p53 vector (Supplementary Figure 9).
Accordingly, the ectopic expression of mutp53R175H or
mutp53R273H clearly determined the repression of AMPK
phosphorylation and the increase of p70S6K phosphorylation
(Figure 5A). To better represent our results, we quantified P-
AMPK/P-p70S6K ratio (Figure 5B), highlighting that wild type
and mutant p53 proteins produced inverse effects on these
signalingpathways.Overall, quantificationandstatistical eval-
uation of the proteins representatively shown in Figure 5A are
reported in Supplementary Figure 10. To address the role of
AMPK phosphorylation mutant p53-dependent, we inhibited
AMPK activity treating the cancer cells with compound C (CC)
or overexpressing a dominant negative (DN) AMPK isoform
(Figure 5C and D). Strikingly, AMPK signaling inhibition by
both CC and DN-AMPK strongly rescued the autophagosome
formation induced by mutant p53 knock down (Figure 5C).
Consistently, in the same conditions of AMPK signaling inhibi-
tion the oncogenic proliferation impaired bymutant p53 knock
down was restored in all three cell lines tested (Figure 5D).
Overall, these results provide robust evidence that mutant
p53 exerts its inhibitory activity on the autophagic signaling
throughout the constitutive blockage of AMPK signaling.Figure 3 e Autophagy-related gene regulation by mutant p53. (A) The ind
oligonucleotides. H1299 cells were transfected with mutp53R175H, mutp53
of the autophagy-related genes ATG12, BECN1, SESN1, SESN2, and DR
mRNA. *p< 0.05 si-p53 vs si-GFP; xp< 0.05 R175H or R273H vsmock.
values were calculated with two-tailed t-test. (B) Box plot of ATG12 and B
cells by elaboration of data set from Freed-Pastor and colleagues (Freed-P
BECN1 mRNAs expression in breast cancer patients (n[ 72 for wt-p53 and
from www.oncomine.org website (Gluck et al., 2012). (D) Kaplan-Meier su
survival (DMFS) of breast cancer patients bearing mutant TP53 gene class
signature. RFS Statistically significant results with p-value [ 0.02, N [ 1
N [ 83). The two compared groups are the patients with the highest expr
expression (black).3.6. Mutant p53 inhibits Beclin1 phosphorylation by
mTOR stimulation and its expression level
Given that mTOR pathway was controlled by mutant p53
(Figure 5), we speculated that our finding was in correla-
tion with the fact that mTOR complex might de-
phosphorylate Beclin1 via ULK1 inhibition impairing the
formation of Beclin1-mediated autophagic protein com-
plexes and autophagy maturation (Russell et al., 2013).
To gain insight into the molecular mechanisms controlling
the Beclin1 expression, we observed that the overexpres-
sion of mutp53R175H or mutp53R273H proteins in AsPC1
cells decreased both Beclin1 phosphorylation in Serine 15
and its total protein expression level (Figure 6A). Accord-
ingly, the depletion of mutant p53 from Panc1 cells
exerted the inverse results (Figure 6A). These data corre-
lated with the Beclin1 mRNA expression shown in
Figure 3.
In line with the findings from Russel and colleagues, we
also investigated whether the stimulation of mTOR signaling
by mutant p53 (shown in Figure 5) may be responsible for
the decrease in levels of Beclin1 phosphorylation. We
observed that the addition of everolimus (RAD001), an inhibi-
tor of mTOR currently used in the therapy of several human
cancers, was able to completely restore Beclin1 phosphoryla-
tion repressed by overexpression of both R175H or R273H
p53 mutant proteins, indicating that mTOR stimulation by
mutant p53 is highly involved in Beclin1 de-phosphorylation
(Figure 6A). Quantification and statistical evaluation of Beclin1
and of its phosphorylated form are shown in Supplementary
Figure 11. Since Beclin1 phosphorylation has been described
to be crucial for ATG proteins interaction during autophago-
some vesicles formation, we investigated the role of Beclin1
repression on overall autophagy inhibition by mutant p53.
We observed that the knockdown of Beclin1 (Supplementary
Figure 12) significantly reduced the autophagosome formation
induced by the depletion of mutant p53 protein (Figure 6B),
thus suggesting a role for Beclin1 repression on the autophagy
pathway inhibition driven by mutant p53. According to this,
the concomitant depletion of mutant p53 and Beclin1 led to
a partial rescue of proliferation ability of cancer cells as
compared to mutant p53 knockdown conditions (Figure 6C).
Overall, our data strongly support the negative effect of
mutant p53 on the Beclin1 functionality throughout the inhi-
bition of its expression and phosphorylation via mTOR
stimulation.icated cell lines were transfected with si-p53 and si-GFP (as control)
R273H or pcDNA3 (mock) vectors for 48 h. Gene expression analysis
AM1 was performed by RT-qPCR and was normalized to GAPDH
All the experiments are representative of three biological replicates. P-
ECN1 mRNAs expression obtained in MDA-MB-468 breast cancer
astor et al., 2012; Rhodes et al., 2004). (C) Box plots of ATG12 and
n[ 72 for mut-p53). Data from Gluck and colleagues were obtained
rvival curves of relapse free survival (RFS) and distant metastasis free
ified according to the expression of atg12, becn1, sesn1, and dram1
88; DMFS Statistically significant results with p-value [ 0.0028,
ession (red) levels of the signature versus the patients with the lowest
Figure 4 eMutant p53 inhibits atg12 expression by interaction with NF-kB p50 subunit. (A) Schematic representation of ATG12 promoter gene
regions containing NF-kB p50 consensus box sequences analyzed in ChIP assays. ATG12 promoter: two regions at 1055 bp (region 1) and 513 bp
(region 2) upstream the first exon of ATG12 gene. The TSS is indicated and it was predicted by Eponine software (Down and Hubbard, 2002). (B)
Cross-linked chromatin derived from sip50-treated SKBr3 cells and from siGFP-transfected control, was immunoprecipitated with the indicated
antibodies or in the absence of antibody, and analyzed by RT-qPCR with specific primers (see Material and Methods or Supplementary Table 2)
for the indicated regions in the Figure 4A. Each point of the experiment was carried out in biological duplicate and each reaction of each sample in
RT-qPCR was carried out in technical replicate. The P-values were calculated with two-tailed t-test. *p< 0.05. (C) (Left panel)
Immunoprecipitations of NF-kB p50 or NF-kB p65 proteins and western blot analysis for p53 binding are performed from lysates of the indicated
cancer cell lines expressing mutant p53 proteins (described in Material and Methods). NF-kB p50 or NF-kB p65 proteins were
immunoprecipitated with their relative rabbit polyclonal antibody and the same amount of rabbit IgG was used as negative control of IP. (Right
panel) Cell lysate from H1299 cells over-expressing mutp53R175H protein was immunoprecipitated with p53 sheep polyclonal antibody. Cells
transfected with the empty vector (pcDNA3) was used as negative control. (D) Cells were transfected with the siRNAp50 or its negative control for
48 h. Gene expression analysis of ATG12 mRNA was performed by RT-qPCR and normalized to GAPDH mRNA. This experiment was a
biological triplicate. The P-values were calculated with two-tailed t-test. Statistically significant results were with p-value< 0.05. (E) Cells were
transfected with siRNAp50 or its relative negative control. Autophagosome formation assay was performed using the incorporation of MDC probe.
Statistical analysis: *p< 0.05 p53 or p50 vs No Ab; x sip50 vs CTRL.
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Figure 5 eMutant p53 inhibits AMPK and stimulates mTOR. (A) Cells were seeded in 100-mm diameter culture dishes and transfected for 48 h
with the pRSuper-p53 vector (shp53) and with plasmids for the ectopic expression of mutant p53 (o.e. R175H; o.e. R273H), or their relative
negative control (shCTRL or mock, respectively). Western blotting analysis from these cells was performed with 50 mg of whole cell extracts and
probed with the indicated antibodies. This analysis was representative of three biological replicates. (B) Quantitative analysis of P-AMPK/P-
p70S6K ratio. The bands shown in (A) were scanned as digital peaks and the areas of the peaks were reported as fold change, as described in
Material and Methods. (C and D) The indicated cell lines were transfected for 48 h with the pRSuper-p53 vector (shp53) or its negative control
(shCTRL), in the absence or presence of 20 mM Compound C (CC) or together the expression vector coding for WT or dominant negative (DN;
mutant R531G) AMPK g2 subunit. Autophagosome formation (C) and cell growth (D) were analyzed by using MDC and crystal violet staining,
respectively. Statistical analysis: *p< 0.05 shp53 vs CTRL; f R175H or R273H vs mock; xp< 0.05 shp53DCC vs shp53; #p< 0.05
shp53DDN-AMPK vs shp53DWT-AMPK.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 9 10193.7. Mutant p53 sensitizes cancer cells to mTOR
inhibition
Everolimus is an inhibitor of mammalian target of rapamycin
(mTOR) routinely used in the targeted therapy of many can-
cers. We aimed to investigate whether cancer cells bearing
mutant p53 might be more responsive to everolimus than
wild type p53 cancer cells, accordingly with the inhibitoryrole of mutant p53 on autophagy via mTOR pathway induc-
tion (Figures 5 and 6). To this end, we incubated everolimus
Panc1, SkBr3 and MCF7 cell lines and observed that the cells
expressingmutant p53 (Panc1 and SKBr3) weremore sensitive
than cells with wild type p53 (MCF7) to the treatment as re-
ported by the IC25 and IC50 values (Figure 7A). To functionally
demonstrate the involvement of mutant p53 on cancer cell
sensitivity to everolimus, we evaluated the response of the
Figure 6 e Mutant p53 inhibits Beclin1. (A) AsPC1 cells were seeded
in 100-mm diameter culture dishes and transfected for 48 h with the
plasmids coding for mutant p53 proteins (R175H or R273H), or with
pCDNA3 as negative control (mock), in the absence or presence of
5 mM everolimus (EVE). Panc1 cells were knocked-down for mutant
p53 expression by 48 h of pRSuper-p53 vector transfection (shp53).
Whole-cell extracts were used for Western blot analysis using the
indicated antibodies. (B and C) Panc1 and SkBr3 cells were seeded in
96-well plates and transfected with the pRSuper-p53 vector (shp53)
and/or si-Beclin1 oligos (siBeclin1). Autophagosome formation (B)
and cell growth (C) were analyzed after 48 h by the transfection using
MDC and crystal violet staining, respectively. These experiments were
biological triplicates. The P-values were calculated with two-tailed t-
test. Statistical analysis: xp< 0.05 shp53DsiBeclin1 vs shp53.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 91020cells after knockdown or overexpression of p53 mutant pro-
teins. Our data reported in Figure 7B, showed that mutant
p53 knockdown significantly decreased Panc1 and SkBr3 cell
response to everolimus treatment if compared to controls.
To corroborate this result, we assessed that the overexpres-
sion of R175H or R273H mutant p53 conferred to p53-null
AsPC1 cells a strong sensitization to everolimus incubation,
as compared to its negative control (mock vector). Moreover,
the dominant negative effect of p53 mutant proteins ectopi-
cally expressed in WTp53 cells (PaCa3), allowed a stronger
impact resulting in a higher response to everolimus incuba-
tion in comparison to the PaCa3 cells under control conditions
(Figure 7B). Overall, these results demonstrated that targeting
the mTOR pathway may represent an effective therapeutic
strategy for cancer patients bearing mutations in the TP53
gene.4. Discussion
Autophagy is a tightly-regulated catabolic process of
cellular self-digestion by which cellular components are
targeted to lysosomes for their degradation. However, the
role of autophagy in modulating cell death is highly depen-
dent on the metabolic context and on the microenviron-
mental conditions in which the cells lie (Lorin et al.,
2013). Key functions of autophagy are aimed to provide en-
ergy and metabolic precursors under conditions of starva-
tion and to alleviate cellular stress removing damaged
proteins and organelles, which are deleterious for cell sur-
vival. Therefore, autophagy appears to serve as a pro-
survival stress response in most settings (Fiorini et al.,
2013; Matsuzawa et al., 2015). Increasing evidence show
its pivotal role in cell death after treatment with anti-
cancer drugs or under particular stressful conditions
(Fiorini et al., 2015a; Fulda and K€ogel, 2015). Thus, despite
the net effect of autophagy in cancer cells is highly contex-
tual, substantial results describe that enforced over-
activation of autophagy can lead to excessive cellular
self-digestion via the autophagosomal-lysosomal pathway
determining autophagic cell death (also named cell death
type II) (Galluzzi et al., 2012). The importance of autophagic
cell death becomes evident by the consideration that it is
able to bypass drug resistance, especially in apoptosis-
refractory tumors, offering new therapeutic options in
overcoming cancer resistance mechanisms (Fulda and
K€ogel, 2015; Schonthal, 2009). Since Avantaggiati and col-
leagues have previously demonstrated that mutant p53 sta-
bility is controlled by lysosomal degradation and not by
proteasomal involvement as occurs for wild type p53
(Choudhury et al., 2013), autophagy inhibition by mutant
p53 may, at least partially, explain also the high expression
levels of mutant p53 itself observed in cancer cells.
Recently Mathew and colleagues have clearly shown how
defects in the autophagic pathway could diminish survival
and enhance tumorigenesis with the concomitant accumu-
lation in the DNA mutations (Mathew et al., 2007). The
high mutation rate and the severe genomic instability are
the most important features of the cancers expressing
mutant p53 proteins (Negrini et al., 2010; Soussi and
Figure 7 e Mutant p53 sensitizes cancer cells to everolimus. (A) Cells were seeded in 96-well plates and treated for 48 h with increasing
concentrations of everolimus. Cell growth was measured using the crystal violet colorimetric assay and IC25 and IC50 values for each cell line tested
have been reported. (B) Cells were seeded in 96-well plates and transfected with pRSuper-p53 vector (shp53) and with the plasmids coding for
mutant p53 proteins (R175H or R273H), or with empty pRSuper (shCTRL) or pCDNA3 (mock), respectively, as negative controls. For each
experimental condition, cells were untreated or treated with 5 mM everolimus for 48 h. Cell growth was determined using the crystal violet
colorimetric assay. The rate of cell growth inhibition corresponds to the effect of everolimus, as compared to vehicle (untreated), in each indicated
transfection condition. These experiments were at least biological triplicates. The P-values were calculated with two-tailed t-test. Statistical
analysis: *p< 0.05 shp53 vs shCTRL; xp< 0.05 R175H or R273H vsmock. (C)Model of the molecular mechanism unraveled in the present study.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 0 0 8e1 0 2 9 1021Wiman, 2007). Intriguingly, in this study we intended to
deeply investigate the molecular mechanisms related to
autophagy inhibition by GOF p53 mutants, which can be
summarized with the following considerations schemati-
cally illustrated in Figure 7C: i) mutant p53 inhibits the
expression of a panel of autophagy-related genes, includingbecn1, dram1, sesn1/2, and atg12; ii) autophagy inhibition by
mutant p53 is mediated by its interaction with p50 NF-kB
subunit on the atg12 gene promoter; iii) mutant p53 inhibits
SESN1/AMPK axis and stimulates mTOR pathway; iv)
mutant p53 inhibits P-Beclin1 via mTOR sensitizing cancer
cells to everolimus.
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cytoplasmic localization is the preponderant requirement for
mutant p53 to inhibit autophagy indicating that those variants
of mutant p53 that preferentially localize in the cytoplasm
effectively repress autophagy, whereas p53 mutants that
display a prominently nuclear distribution fail to inhibit it
(Morselli et al., 2008). However, these previous observations
exclusively reached by mutant p53 over-expression assays
are not confirmed by our investigation. Indeed, we reveal
that all tested GOF p53 mutant variants, listed in Table 1, ac-
quire the property to inhibit autophagy irrespectively of their
tissue of origin, such as breast, pancreas or lung, or of their
prevalent subcellular localization previously determined by
Morselli et al. (Morselli et al., 2008). In addition, our results
indicate that the repression of the autophagic machinery is
functional to the hyper-proliferating and anti-apoptotic activ-
ities of these hot-spot p53 mutants in cancer cells. Very
recently, Gu et al. have identified an autophagy-related prog-
nostic signature for breast cancer (Gu et al., 2015)
analyzing six independent public-domain microarrays from
GEO database. They reported that inactivation of autophagy
was associated with shortened survival of breast cancer pa-
tients and that a set of eight genes (bcl2, birc5, eif4ebp1, ero1L,
fos, gapdh, itpr1 and vefgA) were assigned as an autophagy-
related prognostic signature for breast cancer. However,
despite that their statement is consistent with our data, the
genes identified by Gu et al. have a high level of functional
versatility thus lacking in autophagy specificity of the signa-
ture. In this study, we show that low expression of atg12,
dram1, sesn1 and becn1 autophagy-related signature was
significantly associated with a poor prognosis in the mutant
p53 breast cancer subgroup. This consideration strongly rein-
forces the statement of autophagy as an anti-proliferative and
pro-apoptotic event that cancer cells try to escape in vivo.
Furthermore, autophagy-deficient cell lines increase DNA
double-strand breaks and other chromosome abnormalities
suggesting a role for the autophagic pathway in suppressing
genome damage and inhibition of pro-tumorigenic process
(Mathew et al., 2007). In addition, we demonstrated a
protein-protein interaction between p50 NF-kB subunit and
mutant p53 and their recruitment in two regions of atg12 pro-
moter. Intriguingly, we observed that the depletion of p50 pro-
tein increased both atg12 mRNA expression and
autophagosome formation in cancer cells bearing mutant
p53. Therefore, it is tempting to speculate that the interaction
betweenmutant p53 and the p50-p50 homodimer could repre-
sent a novel molecular mechanism by which mutant p53 is
able to repress the expression of its target genes (Guan et al.,
2005; Tong et al., 2004). The existence of this functional inter-
action might have a great impact in cancer cell biology
contributing to the discovery of new drugs potentially able
to inhibit this oncogenic mechanism.
Concerning signal transduction pathways involved in
autophagy inhibition, our data are in accordancewith a recent
study of Myers and colleagues which indicated that under
conditions of energy stress, GOF p53 mutants, but not
WTp53, can bind to the AMPKa subunit inhibiting AMPK
signaling (Zhou et al., 2014). We further documented that
mutant p53 suppressed the expression of Sestrins which
have been described to act as AMPK activators through thedirect interaction with AMPK complex favoring its phosphor-
ylation by upstream kinases (Budanov and Karin, 2008;
Morrison et al., 2015; Sanli et al., 2012). Overall, we showed
that AMPK signaling inhibition was functionally implicated
on autophagy counteraction by mutant p53. Moreover, we
demonstrated that mTOR pathway stimulation by mutant
p53 was able to repress Beclin-1 phosphorylation, which is
required for activating the ATG14L-VPS34 complex during
autophagosome formation (Russell et al., 2013), thus orches-
trating autophagy machinery inhibition driven by mutant
p53. Indeed, it is important to highlight that mutant p53
orchestrated a number of adjustments aimed at inhibiting
the autophagic flow starting from ATG regulation to autopha-
gic vesiscles formation and their fusion with lysosomes. We
finally underline the translational relevance of our data con-
cerning the potential use of the mTOR inhibitor everolimus
for cancer patients carrying mutant TP53 gene.5. Conclusions
Overall, we have observed that mutant p53: i) inhibited mRNA
and protein expression levels of various key ATGs (Figures 3, 4,
5 and 6); ii) inhibited the formation of autophagic vesicles and
formation of themature isoform of LC3 (Figure 1); iii) inhibited
fusion of the autophagic vesicleswith lysosomes, formation of
autolysosomes and lysosomal acidification of the lumen
(Figure 1); iv) inhibited AMPK signaling and stimulated mTOR
pathway making cancer cells bearing mutant p53 susceptible
tomTOR inhibition (Figures 5 and 7). Altogether these observa-
tions also provided new prognostic tools and innovative in-
sights into mutant p53 GOF activities in cancer cell biology,
strongly supporting mTOR inhibition as a personalized thera-
peutic strategy for cancer patients carrying mutant p53.Conflict of interest
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